We are pleased to share that Mercurna has reached its scientific and IP milestones of the RedMedtech Discovery Fund II (RMDFII) by providing exciting data (in vitro and in vivo) on mCura1, Mercurna’s lead formulation for chronic kidney disease. We will use the second tranche of RMDFII financing to further demonstrate the safety and efficacy of mCura1. Mercurna aims to deliver a proof-of-concept in a clinically relevant mouse model within the next few months.
The RMDFII is part of RedMedtech Ventures and operates in collaboration with Health Valley, Radboudumc, Saxion, Oost NL

 

Back